Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 4997-4999

  Ofran, Yishay ^a   Ritz, Jerome ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; HLA A ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CD8+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION; ALLOTRANSPLANTATION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; NEOPLASM; REVIEW;

GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 52649112654     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0857     Document Type: Short Survey

References (13)

1. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006;90:133-73.
2. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999;96:8639-44.
3. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23.
4. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-14.
5. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8.
6. Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci 2007;98:1139-46.
7. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003;197:1279-89.
8. MullallyA, RitzJ. Beyond HLA:The significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109:1355-62.
9. + cytotoxic T cells from renal cell carcinoma patients after allogenic hematopoietic cell transplantation. Clin Cancer Res 2008;14:5260-9.
10. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008;118:1099-109.
11. Tykodi SS, Warren EH, Thompson JA, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004;10:7799-811.
12. Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008;5:256-67.
13. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.